FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...
Endpoints Weekly covers ASH conference highlights, FDA discussions on Moderna's RSV vaccine safety, Biosecure Act exclusion, and industry updates from biotech leaders.
Organon won a label expansion for the steroid-free topical cream it picked up from its October acquisition of Dermavant.
Bicycle Therapeutics reports mixed data for zelenectide pevedotin in cancer trials, with 60% response rate in urothelial ...
McKinsey fined $650M for helping boost OxyContin sales, misleading FDA about conflicts. Ex-partner Martin Elling charged with ...
The FDA is pushing back against claims that its safety restrictions for the abortion pill mifepristone are “onerous and ...
Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron
The billion-dollar AI-focused startup Xaira Therapeutics deepened its C-suite this week, hiring former Roche executive Paulo ...
Boundless Bio is trimming its oncology pipeline in the wake of disappointing cancer data and switching up its leadership just ...
The European Medicines Agency’s human medicines committee (CHMP) handed down 17 recommendations for drug approvals on Friday ...
In an attempt to continue its I&I dominance beyond Humira, Skyrizi and Rinvoq, AbbVie is buying up another small autoimmune ...
Demis Hassabis has no interest in a laboratory. The Nobel Prize-winning artificial intelligence pioneer is betting big on ...
San Antonio Breast Cancer Conference featured updates on VEGF bispecifics, oral protein degraders, and data from BeiGene, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback